These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 39256860

  • 21. Response evaluation after immunotherapy in NSCLC: Early response assessment using FDG PET/CT.
    Park S, Lee Y, Kim TS, Kim SK, Han JY.
    Medicine (Baltimore); 2020 Dec 18; 99(51):e23815. PubMed ID: 33371161
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Diffusion-weighted MRI and 18F-FDG PET/CT in assessing the response to neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
    Xu X, Sun ZY, Wu HW, Zhang CP, Hu B, Rong L, Chen HY, Xie HY, Wang YM, Lin HP, Bai YR, Ye Q, Ma XM.
    Radiat Oncol; 2021 Jul 19; 16(1):132. PubMed ID: 34281566
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Correlation study on 18F-FDG PET/CT metabolic characteristics of primary lesion with clinical stage in lung cancer.
    Hu WD, Wang HC, Wang YB, Cui LL, Chen XH.
    Q J Nucl Med Mol Imaging; 2021 Jun 19; 65(2):172-177. PubMed ID: 30916535
    [Abstract] [Full Text] [Related]

  • 29. Different Prognostic Values of Dual-Time-Point FDG PET/CT Imaging Features According to Treatment Modality in Patients with Non-Small Cell Lung Cancer.
    Jang SJ, Lee JW, Lee JH, Jo IY, Lee SM.
    Tomography; 2022 Apr 08; 8(2):1066-1078. PubMed ID: 35448721
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
    Shang J, Ling X, Zhang L, Tang Y, Xiao Z, Cheng Y, Guo B, Gong J, Huang L, Xu H.
    Eur J Nucl Med Mol Imaging; 2016 Oct 08; 43(11):1945-53. PubMed ID: 27236466
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. What 18F-FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Non-Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria?
    Turgeon GA, Iravani A, Akhurst T, Beaulieu A, Callahan JW, Bressel M, Cole AJ, Everitt SJ, Siva S, Hicks RJ, Ball DL, Mac Manus MP.
    J Nucl Med; 2019 Mar 08; 60(3):328-334. PubMed ID: 30030343
    [Abstract] [Full Text] [Related]

  • 37. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, Shih MC, Shimada N, Chen S, Salgia R, Appelbaum DE, Suzuki K, Chen CT, Pu Y.
    Eur J Nucl Med Mol Imaging; 2012 Jan 08; 39(1):27-38. PubMed ID: 21946983
    [Abstract] [Full Text] [Related]

  • 38. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
    Zhang F, Wu X, Zhu J, Huang Y, Song X, Jiang L.
    Eur J Nucl Med Mol Imaging; 2021 Sep 08; 48(10):3250-3259. PubMed ID: 33630146
    [Abstract] [Full Text] [Related]

  • 39. Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0.
    Odawara S, Kitajima K, Katsuura T, Kurahashi Y, Shinohara H, Yamakado K.
    Eur J Radiol; 2018 Apr 08; 101():65-71. PubMed ID: 29571803
    [Abstract] [Full Text] [Related]

  • 40. Evaluation of response to stereotactic body radiation therapy for nonsmall cell lung cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.
    Han J, Song Q, Guo F, Du R, Fang H, Kang J, Lu Z.
    Nucl Med Commun; 2022 Jun 01; 43(6):717-724. PubMed ID: 35354781
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.